STRATA Skin Sciences, Inc. (SSKN) Cash & Equivalents (2010 - 2025)

STRATA Skin Sciences has reported Cash & Equivalents for 16 years, with the latest figure at $7.9 million in Q4 2025.

• Quarterly Cash & Equivalents rose 8.97% year-over-year to $7.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.9 million (up 8.97% YoY) and the FY2025 annual result came in at $7.9 million, up 8.97% from the prior year.
• Cash & Equivalents rose to $7.9 million in Q4 2025 per SSKN's latest filing, from $7.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $13.0 million in Q3 2021 and troughed at $2.8 million in Q1 2023.
• A 5-year average of $7.9 million and a median of $7.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 74.14% in 2023, then surged 85.38% in 2024.
• Over 5 years, Cash & Equivalents stood at $12.6 million in 2021, then sank by 56.83% to $5.4 million in 2022, then rose by 24.84% to $6.8 million in 2023, then rose by 7.03% to $7.3 million in 2024, then advanced by 8.97% to $7.9 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.9 million, $7.1 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.